ADC Therapeutics :
ADCT
ADCT
Stock Data
$3.62
$0.07 (1.97%)
Asset Type
Common Stock
Exchange
NYSE
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
ADC Therapeutics SA is a biotechnology firm focused on developing treatments for cancer. It specializes in creating antibody drug conjugates (ADCs) aimed at combating hematological malignancies and solid tumors. Its leading product, ZYNLONTA, is undergoing trials for specific lymphoma conditions. The company is also working on several other ADCs targeting various cancers, including a notable project in Hodgkin lymphoma and treatments for solid tumors and leukemia. Founded in 2011 and based in Switzerland, ADC Therapeutics collaborates with several global entities to advance its research and development efforts.
All ADC Therapeutics Articles
21 Articles